Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer

The purpose of this study is to evaluate the safety, tolerability and preliminary activity of IEV407 as a single agent and in combination with endocrine therapy (fulvestrant or letrozole) in patients with advanced hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-negative) breast cancer.

Trial Details

NCT ID
NCT07604571
Phase
PHASE1
Sponsor
Novartis Pharmaceuticals
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • IEV407
  • Fulvestrant
  • Letrozole
Locations (sample)
  • New Haven, Connecticut, United States|41.30815,-72.92816
  • Kansas City, Kansas, United States|39.11417,-94.62746
  • Dallas, Texas, United States|32.78306,-96.80667
  • Toronto, Ontario, Canada|43.65333,-79.38389
  • Marseille, France|43.29695,5.38107

Key Eligibility Criteria

  • Age ≥ 18 years old
  • Patients with one of the following indications:
  • Dose escalation (IEV407 single agent and in combination with fulvestrant or letrozole):
  • HR+/HER2- aBC with disease progression on or following, or have been intolerant to, at least one line of endocrine-based therapy in combination wit…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →